European Commission grants Teva approval for acquisition of ratiopharm

NewsGuard 100/100 Score
Aug 4 2010

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the Company received approval from the European Commission to proceed with its acquisition of ratiopharm. In connection with this approval and following the Commission's review of this transaction, Teva made certain limited commitments, which are anticipated to have only a marginal affect on the combined companies' activities. Teva now plans to close the transaction in the near future.

Teva was represented before the European Commission by Willkie Farr & Gallagher LLP.

Source:

Teva Pharmaceutical Industries Ltd.

Posted in:

Tags: , , , , ,

Comments (0)

Suggested Reading

The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
St. Jude researchers unveil mechanisms to block PXR and enhance drug potency
Common HIV drugs linked to reduced Alzheimer's disease risk
Georgetown study raises concerns over aspirin's role in breast cancer treatment
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
Research quantifies impact of childhood obesity on long-term health and life expectancy
LabVantage celebrates customer success with record number of software deployments in FY 2024
Study highlights global fertility decline and its implications for the future

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Extended CPAP treatment boosts lung development in premature infants